Table 1.
Baseline characteristics by cohort
| Intervention group | Control group | ||
|---|---|---|---|
| Cohort 1 | |||
| Number of patients | 5390 | 3862 | |
| Women | 3604 (67%) | 2681 (69%) | |
| Age (years) | 36 (30–43) | 35 (29–42) | |
| National identity number recorded | 4767 (88%) | 3184 (82%) | |
| CD4 (cells per μL) | 141 (70–201) | 137 (70–197) | |
| 0–49 | 934 (17%) | 678 (18%) | |
| 50–99 | 949 (18%) | 720 (19%) | |
| 100–199 | 2141 (40%) | 1547 (40%) | |
| 200–350 | 1366 (25%) | 917 (24%) | |
| WHO stage recorded* | 3057 (57%) | 1719 (45%) | |
| Stage I | 1582/3057 (52%) | 551/1719 (32%) | |
| Stage II | 637/3057 (21%) | 470/1719 (27%) | |
| Stage III | 725/3057 (24%) | 653/1719 (38%) | |
| Stage IV | 113/3057 (4%) | 45/1719 (3%) | |
| Weight recorded | 4400 (82%) | 2875 (74%) | |
| Weight (kg) | 59 (14) | 58 (14) | |
| Present tuberculosis | 301 (6%) | 200 (5%) | |
| Admitted in the year before enrolment | 392 (7%) | 313 (8%) | |
| Cohort 2 | |||
| Number of patients | 3029 | 3202 | |
| Women | 2113 (70%) | 2332 (73%) | |
| Age (years) | 38 (32–44) | 38 (32–45) | |
| National identity number recorded | 2859 (94%) | 2958 (92%) | |
| Duration on ART (months) | 13·9 (6·8–21·7) | 13·7 (7·3–22·3) | |
| ART regimen | |||
| First line (stavudine, lamivudine, efavirenz) | 1846 (61%) | 2056 (64%) | |
| First line (stavudine, lamivudine, nevirapine) | 1012 (33%) | 1011 (32%) | |
| Second line (zidovudine, didanosine, lopinavir) | 37 (1%) | 28 (1%) | |
| Other | 109 (4%) | 100 (3%) | |
| Not known | 25 (1%) | 7 (<1%) | |
| Viral load <400 copies per mL | 2378 (79%) | 2507 (78%) | |
| Weight recorded | 2886 (95%) | 3128 (98%) | |
| Weight (kg) | 61 (13) | 62 (13) | |
| Present tuberculosis | 241 (8%) | 186 (6%) | |
| Admitted in the year before enrolment | 282 (9%) | 299 (9%) | |
Data are n (%), median (IQR), n/N (%), or mean (SD). ART=antiretroviral theraoy.
*
Staged just before initiation of ART, usually after enrolment.